NeuroHagana (NH) develops an injectable emergency treatment for neurotrauma, irrespective of its type or severity. The novel treatment acts immediately to protect against the main factor in Neurotrauma pathology: Glutamate Excitotoxicity.
NH’s technology has been pre-clinically validated in animal models of Spinal Cord Injury, Traumatic Brain Injury, and Athletes Concussion, with no side effects. The new treatment reduces the toxic impact of excessive Glutamate levels in the Central Nervous System, preventing irreversible neuronal damage and physical disabilities.
First applications will be Spinal Cord Injury, first in Europe and USA. Other applications will be Traumatic Brain Injury and Stroke.
Essential for paramedics, hospital trauma units, first aid teams and military forces, the new innovative drug aims to become a vital component of any core emergency kit, preventing permanent disabilities of the injured people and giving them the opportunity to regain their freedom.
